Buy Xeloda

Xeloda

Xeloda: Capecitabine Overview

Xeloda is a brand-name medication that contains the active ingredient capecitabine. It belongs to the oncology support category and is supplied as a 500 mg oral pill. In the United Kingdom, Xeloda is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).

How Capecitabine Works in the Body

Capecitabine is a pro-drug that is converted to the chemotherapy agent 5-fluorouracil (5-FU) after oral ingestion. The conversion occurs in several steps:

• First, capecitabine is absorbed from the gastrointestinal tract.
• Second, hepatic enzymes (carboxylesterase) transform it into 5′-deoxy-5-fluorocytidine (5′-DFCR).
• Third, the liver and tumor tissues further metabolise 5′-DFCR to 5′-deoxy-5-fluorouridine (5′-DFUR).
• Finally, the enzyme thymidine phosphorylase-found in higher concentrations within many tumors-converts 5′-DFUR to the active cytotoxic agent 5-FU.

5-FU interferes with DNA synthesis by inhibiting thymidylate synthase, leading to impaired tumor cell replication and eventual cell death. Because the last conversion step is more active in tumour tissue, capecitabine aims to deliver higher concentrations of 5-FU within the cancer itself while limiting systemic exposure.

Onset of action generally occurs within a few days of starting therapy, with peak plasma levels of 5-FU reached after several hours post-dose. The drug’s half-life is short, but the pro-drug formulation allows convenient twice-daily oral dosing.

Conditions Treated with Xeloda

Capecitabine is approved in the UK for the following indications, as listed by the MHRA and European Medicines Agency (EMA):

• Metastatic colorectal cancer (in combination with oxaliplatin or as monotherapy after failure of fluoropyrimidine-based therapy).
• Adjuvant treatment of stage III colon cancer following surgical resection.
• Metastatic breast cancer in patients who have previously received anthracycline- and taxane-based chemotherapy.

These approvals are based on large-scale clinical trials that demonstrated improved disease-free survival or overall response rates compared with alternative regimens. Capecitabine is prescribed by oncologists who assess each patient’s disease stage, prior treatment history, and overall health status.

Off-Label and Investigational Applications

Evidence from peer-reviewed studies suggests capecitabine may have activity in other solid tumours, such as gastric cancer, pancreatic cancer, and head-and-neck squamous cell carcinoma. However, these uses are not approved by the MHRA and should only be considered within clinical trials or under specialist supervision.

Off-label use requires medical supervision and individualized risk assessment.

Who Should (Not) Use Xeloda?

Ideal Patient Profile

• Adults with the approved cancer types who have adequate organ function (renal, hepatic, bone marrow).
• Patients able to swallow oral pills and adhere to a twice-daily dosing schedule.

Absolute Contraindications

• Known hypersensitivity to capecitabine, 5-FU, or any excipients in the tablet.
• Severe renal impairment (creatinine clearance < 30 mL/min) because active metabolites accumulate.
• Pregnant or breastfeeding women-capecitabine is teratogenic and can be excreted in breast milk.

Relative Contraindications

• Moderate hepatic impairment (bilirubin > 1.5 × upper limit of normal).
• Pre-existing cardiac disease (e.g., recent myocardial infarction) due to potential coronary vasospasm.
• Concomitant use of drugs that strongly affect dihydropyrimidine dehydrogenase (DPD) activity (e.g., certain antivirals).

Special Populations

• Pregnancy/Lactation: Capecitabine is classified as contraindicated. Effective contraception is required during treatment and for at least 3 months after the final dose.
• Elderly: Dose reductions are often needed because renal function declines with age.
• Patients with Dihydropyrimidine Dehydrogenase Deficiency: This rare enzymatic defect markedly increases toxicity; testing is advised before initiating therapy.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Diarrhoea - often mild to moderate; maintain hydration and consider loperamide if needed.
• Hand-foot syndrome (palmar-plantar erythrodysesthesia) - redness, swelling, or painful peeling of the palms and soles.
• Nausea and vomiting - can be mitigated with anti-emetic agents.
• Fatigue - generally improves with supportive care and rest.

Serious Adverse Events

• Severe neutropenia or thrombocytopenia - may predispose to infection or bleeding; requires regular blood-count monitoring.
• Cardiac toxicity - rare cases of angina, myocardial infarction, or arrhythmia have been reported.
• Severe hand-foot syndrome - can necessitate dose interruption or discontinuation.

If any of the above severe reactions occur, patients should seek immediate medical attention.

Drug Interactions

• Major: Concurrent use of other fluoropyrimidines (e.g., 5-FU) can cause cumulative toxicity.
• Moderate: Drugs that inhibit or induce CYP2C9 (e.g., fluconazole, rifampicin) may alter capecitabine metabolism.
• DPD inhibitors (e.g., sorivudine) dramatically increase capecitabine exposure and are contraindicated.

Patients should provide a full medication list-including over-the-counter drugs, supplements, and herbal products-to their oncology team.

Food and Lifestyle Interactions

• Food: Capecitabine can be taken with or without food; however, taking it with a light snack may reduce gastrointestinal upset.
• Alcohol: Moderate consumption is acceptable, but excessive alcohol may worsen liver toxicity.
• Driving: No specific impairment is expected, but severe fatigue or neuropathy could affect safety.

How to Take Xeloda

Standard Dosing (Using 500 mg Tablets)

• Typical regimen: 1250 mg/m² taken twice daily (approximately 12 hours apart) for 14 consecutive days, followed by a 7-day rest period.
• Administration: Swallow each 500 mg tablet whole with a glass of water; do not crush or chew.
• Cycle length: 21 days (14 days on, 7 days off) is the most common schedule, but the exact plan is individualized by the treating oncologist.

Adjustments for Special Populations

• Renal impairment: Reduce dose by 25 % if creatinine clearance is 30-50 mL/min; avoid use if < 30 mL/min.
• Hepatic impairment: Consider a 25 % dose reduction for moderate dysfunction.
• Elderly: Start at the lower end of the dosing range and titrate based on tolerance and blood-test results.

Missed Dose

If a dose is missed, take it as soon as remembered provided there is at least 6 hours before the next scheduled dose. Do not double-dose.

Overdose

Signs may include severe nausea, vomiting, diarrhoea, and profound bone-marrow suppression. Seek emergency care; supportive measures and possible use of leucovorin rescue are recommended under specialist guidance.

Discontinuation

Abrupt cessation is acceptable if toxicity becomes unmanageable. In some cases, a gradual taper may be advised to minimise rebound effects, but the oncologist determines the appropriate approach.

Monitoring and Follow-Up

• Complete blood count (CBC): Weekly during the first two cycles, then at each follow-up visit.
• Renal function (serum creatinine, eGFR): Baseline and at least every 3 weeks.
• Liver enzymes: Baseline and periodic monitoring, especially in patients with hepatic disease.
• Dermatologic assessment: Prompt evaluation of hand-foot syndrome severity.
• Cardiac evaluation: Consider ECG or cardiac biomarkers if the patient reports chest discomfort or has pre-existing heart disease.

Patients should report new or worsening symptoms promptly. Regular oncology appointments allow dose adjustments and supportive care.

Storage and Handling

• Keep tablets in their original blister pack, stored at room temperature (15-30 °C), away from excess moisture and direct sunlight.
• Do not use the medication after the printed expiry date.
• Dispose of unused tablets according to local pharmacy take-back programs or the UK’s NHS guidelines for safe disposal of medicines.

Medication-Specific Glossary

Pro-drug

An inactive compound that is metabolised in the body to produce an active pharmacologic agent-in this case, capecitabine converting to 5-fluorouracil.

Thymidine Phosphorylase

An enzyme that catalyses the final step of capecitabine activation; it is often present at higher levels in tumour tissue, facilitating selective drug activation.

Hand-Foot Syndrome

A dose-limiting dermatologic toxicity characterised by redness, swelling, and desquamation of the palms and soles.

Dihydropyrimidine Dehydrogenase (DPD) Deficiency

A genetic condition resulting in reduced breakdown of fluoropyrimidines, dramatically increasing the risk of severe toxicity.

Medical Disclaimer

This article provides educational information about Xeloda and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.